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Chronic kidney disease is characterized, in part, as a state of
decreased production of 1,25-dihydroxyvitamin D
(1,25(OH)2D); however, this paradigm overlooks the role of
vitamin D catabolism. We developed a mass spectrometric
assay to quantify serum concentration of 24,25-
dihydroxyvitamin D (24,25(OH)2D), the first metabolic
product of 25-hydroxyvitamin D (25(OH)D) by CYP24A1, and
determined its clinical correlates and associated outcomes
among 278 participants with chronic kidney disease in the
Seattle Kidney Study. For eGFRs of 60 or more, 45–59, 30–44,
15–29, and under 15ml/min per 1.73m2, the mean serum
24,25(OH)2D concentrations significantly trended lower from
3.6, 3.2, 2.6, 2.6, to 1.7 ng/ml, respectively. Non-Hispanic black
race, diabetes, albuminuria, and lower serum bicarbonate
were also independently and significantly associated with
lower 24,25(OH)2D concentrations. The 24,25(OH)2D
concentration was more strongly correlated with that of
parathyroid hormone than was 25(OH)D or 1,25(OH)2D. A
24,25(OH)2D concentration below the median was associated
with increased risk of mortality in unadjusted analysis, but
this was attenuated with adjustment for potential
confounding variables. Thus, chronic kidney disease is a state
of stagnant vitamin D metabolism characterized by decreases
in both 1,25(OH)2D production and vitamin D catabolism.
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Chronic kidney disease (CKD) is characterized as a state of
active vitamin D deficiency. Seminal studies published in the
1970s demonstrated that the kidney produces the majority
of circulating 1,25-dihydroxyvitamin D (1,25(OH)2D), the
potent hormonal form of vitamin D, from 25-hydroxyvita-
min D (25(OH)D).1–5 Owing in large part to 1,25(OH)2D
deficiency, people with CKD develop secondary hyperpar-
athyroidism and bone disease.6,7 Treatment of patients with
CKD using 1,25(OH)2D and other activated vitamin D
receptor agonists is now standard of care.8
Compared with the focus on decreased renal production
of 1,25(OH)2D, relatively little attention has been paid to
the potential role of altered vitamin D catabolism in CKD.
Steady-state concentrations of vitamin D metabolites in
blood and target tissues must necessarily represent a balance
of production and catabolism. CYP24A1 is the primary
enzyme responsible for the multistep catabolism of both
25(OH)D and 1,25(OH)2D. CYP24A1 is found in most
tissues in the body and is rapidly induced by 1,25(OH)2D.
9–11
In the kidney, CYP24A1 transcription is also induced by
fibroblast growth factor-23 (FGF-23) and suppressed by
parathyroid hormone (PTH).10,12 In CKD, net effects of
declining kidney function and rising FGF-23 and PTH con-
centrations on vitamin D catabolism are not clear.
The most abundant product of 25(OH)D catabolism
by CYP24A1 is 24,25-dihydroxyvitamin D (24,25(OH)2D),
which has a circulating half-life of B7 days and is present
in ng/ml concentrations.13 These characteristics make
24,25(OH)2D amenable to clinical measurement and an
attractive potential biomarker of vitamin D catabolism.
In this study, we apply a novel assay to measure circulating
24,25(OH)2D concentrations along with a comprehensive
panel of other circulating vitamin D metabolites and
regulatory hormones in people with CKD. We then examine
the clinical correlates of 24,25(OH)2D and the associations of
24,25(OH)2D concentration with secondary hyperparathyr-
oidism and death.
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RESULTS
Participant characteristics
At baseline, study participants had a mean age of 61 years;
83% were male, 68% were white, 55% had diabetes, and 95%
had hypertension (Table 1). Mean estimated glomerular
filtration rate (eGFR) was 46ml/min per 1.73m2. Partici-
pants with lower 24,25(OH)2D concentrations were more
likely to be older and non-white, have a history of diabetes or
coronary artery disease (CAD), have higher body mass index,
and were less likely to take cholecalciferol supplements.
Correlates of 24,25(OH)2D
Serum 24,25(OH)2D concentration was positively correlated
with eGFR, particularly for eGFR values o60ml/min per
1.73m2 (R2¼ 0.07, Po0.0001, Figure 1a). Similarly,
1,25(OH)2D was positively correlated with eGFR (R
2¼ 0.18,
Po0.0001, Figure 1b) whereas 25(OH)D concentration
showed no relationship with eGFR (R2¼ 0.01, P¼ 0.23,
Figure 1c). FGF-23 was strongly, negatively correlated with
eGFR (R2¼ 0.52, Po0.0001) as was PTH (R2¼ 0.33,
Po0.0001, Figure 2). Serum 24,25(OH)2D concentration
was correlated with serum 25(OH)D concentration but not
with serum 1,25(OH)2D concentration (Figure 3). FGF-23
was strongly correlated with 1,25(OH)2D but was not
correlated with 24,25(OH)2D or 25(OH)D in unadjusted
analyses (Figure 4).
In adjusted analysis, characteristics that were significantly
associated with lower 24,25(OH)2D concentration included
black race, diabetes, lower eGFR, lower 25(OH)D concentra-
tion, and lower serum bicarbonate concentration (Table 2).
All of these associations persisted after further adjustment
for 1,25(OH)2D, PTH, and FGF-23 concentration. Inverse
associations of 24,25(OH)2D concentration with urine
albumin–creatinine ratio (ACR) were of borderline statistical
significance. Cholecalciferol use was not associated with
24,25(OH)2D concentration after adjustment for 25(OH)D.
After adjustment, age, sex, calcitriol use, serum phosphate,
body mass index, smoking status, and CAD were not
significantly associated with 24,25(OH)2D concentration.
With adjustment, FGF-23 concentration was associated
with log-transformed 24,25(OH)2D concentration (41%
higher 24,25(OH)2D per twofold increment in FGF-23,
Po0.001) but not untransformed 24,25(OH)2D concen-
tration (Table 2).
Associations of vitamin D metabolites with PTH
24,25(OH)2D was negatively correlated with PTH (Figure 5;
r¼0.44, Po0.001). This association was stronger than that
of either 1,25(OH)2D (r¼0.16, P¼ 0.01) or 25(OH)D
(r¼0.22, Po0.001). After adjustment for age, sex, race,
eGFR, calcitriol use, cholecalciferol use, diabetes, serum
bicarbonate, calcium, phosphate, urine ACR, 1,25(OH)2D,
and 25(OH)D; each 1 ng/ml lower 24,25(OH)2D was associated
with an estimated 13% higher geometric mean PTH (95%
confidence interval (CI) 6–19%, Po0.001), whereas neither
1,25(OH)2D nor 25(OH)D were significantly associated with
PTH. Lower 24,25(OH)2D concentration was associated
with hyperparathyroidism (PTH 488 pg/dl) in a parallel
adjusted model, with and odds ratio of 1.97 (95% CI
1.32–2.94, P¼ 0.001) for every 1 ng/ml lower 24,25(OH)2D
concentration.
Association of vitamin D metabolites with mortality
Mean follow-up time for the cohort was 2.7 years (range
0–6.4 years). The crude incidence rate of death among the
cohort was 7 per 100 person-years. In the unadjusted Cox
model, 24,25(OH)2D concentration below the cohort median
(2.4 ng/ml) was significantly associated with increased risk
of death (hazard ratio 2.04, 95% CI 1.24–3.36, P¼ 0.005,
Supplementary Figure S2 online). With adjustment for age,
gender, race, eGFR, urine ACR, diabetes, CAD, serum
bicarbonate, and serum 25(OH)D, low 24,25(OH)2D had a
hazard ratio for death of 1.60 (95% CI 0.71–3.64 P¼ 0.26).
Cox regression with 24,25(OH)2D as a continuous exposure
demonstrated an unadjusted hazard ratio of 0.78 (95% CI
0.66–0.91, P¼ 0.002) per ng/ml higher 24,25(OH)2D con-
centration and adjusted hazard ratio 0.88 (95% CI 0.66–1.16,
P¼ 0.37) per ng/ml higher 24,25(OH)2D concentration.
These associations were not affected by additional adjustment
for 1,25(OH)2D, PTH, or FGF-23.
DISCUSSION
Lower eGFR was strongly associated with lower circulating
24,25(OH)2D concentration in a clinic-based CKD popula-
tion. Black race, diabetes, lower serum bicarbonate concen-
tration, lower serum 25(OH)D concentration, and higher
urine ACR were also independently associated with lower
24,25(OH)2D concentration. Serum 24,25(OH)2D concentra-
tion was strongly negatively correlated with serum PTH and
hyperparathyroidism, more so than either 25(OH)D or
1,25(OH)2D. Low concentration of 24,25(OH)2D was asso-
ciated with increased risk of death in unadjusted survival
analysis but lost statistical significance after adjustment for
potential confounders.
CKD is widely viewed as a state of reduced 1,25(OH)2D
production.1,8,14 Our finding of lower 24,25(OH)2D concen-
trations with lower eGFR suggests that CKD is more accurately
described as a state of stagnant vitamin D metabolism, with
decreased vitamin D catabolism in addition to diminished
1,25(OH)2D production. This conclusion is supported by a
study reporting a markedly prolonged 25(OH)D half-life in
anephric patients compared with normal controls, as mea-
sured using injection of radiolabeled 25(OH)D.15 Clinically,
our data suggest that 1,25(OH)2D administration may not
fully correct vitamin D metabolism in CKD because it
addresses only the production side of vitamin D metabolism.
Stagnant vitamin D metabolism in CKD parallels dysfunction
seen in other metabolic and signaling pathways in
kidney disease, including decreased drug metabolism in the
gastrointestinal tract, cytochrome dysfunction in oxidative
phosphorylation, dysregulated lipid metabolism, and altered
growth hormone signaling.16–19
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The mechanism of lower serum 24,25(OH)2D concentrations
with lower eGFR is not known. It is possible that extrarenal
CYP24A1 is an important source of circulating 24,25(OH)2D
that is downregulated in CKD, perhaps due to tissue-level
1,25(OH)2D deficiency.
9,11 Alternatively, the strong relationship
of circulating 24,25(OH)2D with eGFR may be due to decreased
production of 24,25(OH)2D by the kidney. PTH and FGF-23 are
both elevated in CKD and regulate the renal production of
24,25(OH)2D in a reciprocal manner to 1,25(OH)2D produc-
tion.9,10,12 However, 24,25(OH)2D and 1,25(OH)2D were both
strongly directly correlated with eGFR despite this reciprocal
regulation. In addition, previous animal experimental models
have demonstrated conflicting results regarding renal CYP24A1
expression in CKD, and one human biopsy study showed no
association of CKD with CYP24A1 expression.20–22 In the
Col4a3/ mouse, circulating 24,25(OH)2D concentrations
decline with loss of GFR despite increased renal CYP24A1
expression, suggesting that renal expression and total
enzymatic activity diverge in CKD.23 Together, these obser-
vations suggest that PTH and FGF-23 are not the main
drivers of vitamin D catabolism in CKD. Instead, we believe
that an overall decrease in renal mass, less delivery of
25(OH)D to proximal tubular cells, or lower net metabolic
capacity of the proximal tubular cells is the major
Table 1 | Characteristics of 278 Seattle Kidney Study participants by serum 24,25(OH)2D concentration
Full cohort (N=278) 24,25(OH)2D X2.4 ng/ml (N=142) 24,25(OH)2D o2.4 ng/ml (N=136) P-value
Demographic data
Age (years) 60.7±13.0 60.0±13.3 61.5±12.7 0.38
Male (sex) 231 (83%) 118 (83%) 113 (83%) 0.99
Race 0.001
Non-Hispanic white 190 (68%) 111 (78%) 79 (58%)
Non-Hispanic black 53 (19%) 21 (15%) 32 (24%)
Other 35 (13%) 10 (7%) 25 (18%)
Study site 0.96
VAPSHC 159 (57%) 81 (57%) 78 (57%)
HMC 119 (43%) 61 (43%) 58 (43%)
Medical history
Current smoking 48 (18%) 29 (21%) 19 (14%) 0.14
Diabetes 153 (55%) 66 (46%) 87 (64%) 0.003
Hypertension 264 (95%) 132 (93%) 132 (97%) 0.12
Coronary artery disease 92 (33%) 38 (27%) 54 (40%) 0.02
Medications
Phosphate binder 32 (12%) 14 (10%) 18 (13%) 0.38
Cholecalciferol 46 (17%) 32 (23%) 14 (10%) 0.006
Calcitriol 22 (8%) 8 (6%) 14 (10%) 0.15
Any anti-hypertensive 257 (92%) 127 (89%) 130 (96%) 0.05
Erythropoietin 12 (4%) 7 (5%) 5 (4%) 0.61
Physical examination
Systolic blood pressure (mm Hg) 133±21 130±21 136±22 0.01
Body mass index (kg/m2) 31.5±7.5 29.8±6.1 33.4±8.3 0.0002
Laboratory measurements
Creatinine (mg/dl) 2.0±1.0 1.8±0.95 2.2±1.1 0.0009
eGFR (ml/min per 1.73 m2) 45.9±26.1 50.4±27.2 41.3±24.2 0.003
eGFR groups 0.04
460 ml/min per 1.73 m2 67 (24%) 41 (29%) 26 (19%)
45–59 ml/min per 1.73 m2 46 (17%) 28 (20%) 18 (13%)
30–44 ml/min per 1.73 m2 76 (27%) 32 (23%) 44 (32%)
15–29 ml/min per 1.73 m2 72 (26%) 36 (25%) 36 (26%)
o15 ml/min per 1.73 m2 17 (6%) 5 (4%) 12 (9%)
Urine ACR (mg/g) 132 (19, 696) 111 (15, 445) 213 (27, 1233) 0.05
25(OH)D (ng/ml) 28.6±14.5 37.5±13.3 19.3±8.8 o0.0001
24,25(OH)2D (ng/ml) 2.9±2.1 4.40±1.85 1.3±.6 o0.0001
1,25(OH)2D (pg/ml) 33.1±14.3 34.4±15.5 31.7±12.8 0.19
PTH (pg/ml) 71.9 (43.4, 126.9) 54.3 (35.8, 83.0) 92.0 (63.7, 180.7) o0.0001
FGF-23 (pg/ml) 59.4 (42.4, 97.9) 58.7 (42.7, 94.6) 60.5(40.3, 100.5) 0.86
Abbreviations: ACR, albumin to creatinine ratio; eGFR, estimated glomerular filtration rate; FGF-23, fibroblast growth factor-23; HMC, Harborview Medical Center; 24,25(OH)2D,
24,25-dihydroxyvitamin D; PTH, parathyroid hormone; VAPSHC, Veterans Affairs Puget Sound Health Care Center.
All values mean±s.d. or n (%); except urine ACR, PTH, and FGF-23, which are median (interquartile range).
P-values are two-sided using Wilcoxon rank-sum for continuous variables and chi-squared for proportions.
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determinant of renal 24,25(OH)2D production and serum
24,25(OH)2D concentration.
Small, early studies observed lower 24,25(OH)2D con-
centrations in both pre-dialysis CKD and ESRD.24–28 These
studies, however, used a competitive binding assay that has
the potential for cross-reactivity with 25(OH)D and
1,25(OH)2D. Substantial cross-reactivity has been demon-
strated with a 1,25(OH)2D competitive binding assay
compared with mass spectrometry.29 Moreover, our study
was larger and more diverse than prior studies of
24,25(OH)2D and included a comprehensive panel of other
circulating vitamin D metabolites and regulatory hormones,
allowing assessment of clinical determinants of 24,25(OH)2D
for the first time. We found that 25(OH)D, race, serum
bicarbonate, urine ACR, and diabetes were strong predictors
of 24,25(OH)2D concentration, after adjustment for
eGFR. The association with 25(OH)D is probably a simple
relationship between CYP24A1 substrate and product.
The association with race, however, is more complex, as this
association was present after adjustment for 25(OH)D
concentration. We speculate that the associations of
24,25(OH)2D concentration with diabetes, serum bicarbo-
nate, and ACR are due to proximal tubular dysfunction
that is not fully captured by the measurement of eGFR. The
proximal tubule, which is impaired by diabetes, is the site of
vitamin D metabolism as well as bicarbonate reabsorption,
ammonia production for acid excretion, and protein
reabsorption.30–32
Low 24,25(OH)2D may identify risk of CKD complica-
tions. Low serum 24,25(OH)2D concentration was strongly
associated with hyperparathyroidism, perhaps because
24,25(OH)2D concentration reflects the extent to which
vitamin D metabolism is deranged in CKD. Our results also
provide preliminary evidence that low serum 24,25(OH)2D
concentrations may be related to an elevated risk of death.
Although this association was not statistically significant after
adjustment, participants with 24,25(OH)2D below 2.4 ng/ml
had an estimated 60% greater mortality rate than those with
levels above this threshold. The wide CI (95% CI 29–264%)
indicates that our data are consistent with an increased
mortality risk of substantial magnitude. Further study is
necessary to investigate this potential link.
There was no difference in 25(OH)D concentration across
eGFR in our study. Other studies have variously shown stable
or declining 25(OH)D concentration with lower eGFR.33–36
Our data suggest that 25(OH)D concentrations may not
decrease with falling eGFR due to counterbalanced decre-
ments in both 25(OH)D production and 25(OH)D catabolism.
This study has several strengths. First, it includes a well-
characterized, racially diverse population with a spectrum of
kidney function in whom a comprehensive panel of
circulating vitamin D metabolites and regulatory hormones
were rigorously quantified. To our knowledge, it is the largest
study of 24,25(OH)2D concentration performed to date.
Second, we applied a novel and accurate mass spectrometry
assay for 24,25(OH)2D. Third, we concurrently evaluated
complementary measurements of mineral metabolism. Our
study also has some limitations. Power for detecting
associations with mortality was marginal, and associations
of 24,25(OH)2D with clinical outcomes require further study.
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Figure 1 |Correlations of circulating vitamin D metabolites
with estimated glomerular filtration rate (eGFR). (a) 24,25-
dihydroxyvitamin D (24,25(OH)2D) versus eGFR. (b) 1,25-dihydrox-
yvitamin D (1,25(OH)2D) versus eGFR. (c) 25-hydroxyvitamin
(25(OH)D) versus eGFR. Values estimated using second-degree
fractional polynomial (solid line with gray shading indicating 95%
confidence interval of estimate) are superimposed on standard
scatter plots. Plots are truncated at eGFRo90, but all points were
used for line fit.
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Our study population is derived from only two nephrology
clinic sites and may not be generalizable to the CKD
population as a whole. As CYP24A1 is a multicatalytic enzyme
that not only produces but also degrades 24,25(OH)2D, lower
24,25(OH)2D concentrations in CKD could conceivably result
from increased catabolism of 24,25(OH)2D by CYP24A1
rather than decreased 24,25(OH)2D production. We expect,
however, that all catalytic functions of CYP24A1 are similarly
altered in CKD. Therefore, circulating 24,25(OH)2D likely
reflects overall CYP24A1 activity. Finally, analyses of inter-
related circulating biomarkers were cross-sectional, so causality
cannot be determined.
In conclusion, CKD is a state of stagnant vitamin D
metabolism characterized by decreased vitamin D catabolism
in addition to decreased 1,25(OH)2D production. Decreased
25(OH)D catabolism, as measured by lower circulating
24,25(OH)2D concentration, is associated with increased
risks of secondary hyperparathyroidism and possibly with
death. Further studies are needed to test associations of
24,25(OH)2D with clinical outcomes and to determine whether
24,25(OH)2D is a modifiable therapeutic target in CKD.
MATERIALS AND METHODS
Study population
The Seattle Kidney Study (SKS) is an ongoing nephrology clinic-
based cohort study of people with CKD. Beginning in June of 2004,
participants were recruited from outpatient nephrology clinics at the
Harborview Medical Center and the Veterans Affairs Puget Sound
Health Care Center (VAPSHC) in Seattle, Washington. Inclusion
criteria are age X18 years and either an eGFR p90ml/min per
1.73m2 or a urinary protein to creatinine ratioX30mg/g. Exclusion
criteria are dialysis, previous kidney transplant, inability to provide
informed consent, and expectation of dialysis initiation within 3
months. This study was approved by the University of Washington
Institutional Review Board.
At the time of this study, 531 SKS participants had completed
a baseline study visit including collection of serum specimens. We
excluded 15 participants taking ergocalciferol (vitamin D2) supple-
ments because our assay detected 24,25(OH)2D3 but not
24,25(OH)2D2. Vitamin D2 has an additional methyl group
at the 24-carbon, which may alter hydroxylation at that site. Owing
to cost constraints, we randomly selected a cohort of 278
SKS participants (B50%) for this study. To test associations of
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Figure 2 |Correlations of estimated glomerular filtration
rate (eGFR) with fibroblast growth factor-23 (FGF-23) and
parathyroid hormone (PTH) concentrations. (a) FGF-23 versus
eGFR. (b) PTH versus eGFR. Values estimated using second degree
fractional polynomial models (solid line with gray shading
indicating 95% confidence interval of estimate) are superimposed
on standard scatter plots.
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Figure 3 |Correlations of 24,25-dihydroxyvitamin D
(24,25(OH)2D) concentration with 25-hydroxyvitamin D (25(OH)D)
and 1,25-dihydroxyvitamin D (1,25(OH)2D) concentrations.
(a) 24,25(OH)2D versus 25(OH)D. (b) 24,25(OH)2D vs 1,25(OH)2D.
Values estimated using second degree fractional polynomial
models (solid line with gray shading indicating 95% confidence
interval of estimate) are superimposed on standard scatter plots.
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24,25(OH)2D with mortality using a case–cohort design, we also
studied the remaining 34 of the 531 participants who died during
longitudinal follow-up (Supplementary Figure S1 online). Two
participants taking cinacalcet were included in our analyses. Exclusion
of these two participants did not substantially alter any of the results.
Measurement of 24,25(OH)2D, 25(OH)D, and 1,25(OH)2D
24,25(OH)2D and 25(OH)D were measured simultaneously with
the same extraction and analysis procedures. The full method of
extraction and analysis for 25(OH)D has been described previously.37
The only difference in the combined assay was the use of 50%
n-heptane: 50% methyl-tert-butyl-ether instead of n-heptane alone.
Briefly, 200ml of thawed serum specimens, previously frozen at
80 1C, were alkalinized with sodium hydroxide, covered, vortexed,
and incubated at room temperature for 15min. 25(OH)D2-d3,
25(OH)D3-d6 (Medical Isotopes, Pelham, NH) and 24,25(OH)2D3-d6
(Toronto Research Chemicals, North York, ON, Canada) were added
as internal standards, and specimens were vortexed for an additional
15 s. The extraction solvent (1ml of 50% n-heptane:50% methyl-tert-
butyl-ether) was added, and each aliquot was vortexed for 5min
followed by centrifugation. The aliquots were then placed in a dry ice
acetone bath for 50min to freeze the lower aqueous layer. The organic
layer was removed, dried, and reconstituted in 100ml 0.5mg/ml
PTAD in acetonitrile. Ten microliters of dissolved extracts were
injected and developed using a Acquity UPLC (Waters, Milford, MA).
Compounds were then analyzed using isotope dilution tandem mass
spectrometry in ESI-positive mode on a Xevo TQ (Waters). Dwell
time was 42ms. The calibration for the measurement of 25(OH)D
was verified using SRM 972 from NIST with accuracy of 91–95% for
25(OH)D3 and 100–116% for 25(OH)D2. The method has lower
limits of quantification (20% coefficient of variation) of 0.5, 1.0, and
5.0 ng/ml for 24,25(OH)2D3, 25(OH)D3, and 25(OH)D2, respectively.
Interassay imprecision was 8.58% at 1.5 ng/ml for 24,25(OH)2D3,
4.40% at 10.4 ng/ml for 25(OH)D3, and 4.35% at 9.7 ng/ml for
25(OH)D2. Among a subset of 22 subjects with repeat 24,25(OH)2D
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Figure 4 |Correlations of fibroblast growth factor-23 (FGF-23)
concentration with circulating vitamin D metabolites.
(a) 24,25-dihydroxyvitamin D (24,25(OH)2D), (b) 25-hydroxyvitamin D
(25(OH)D), and (c) 1,25-dihydroxyvitamin D (1,25(OH)2D). Line fit
with linear regression. P-values are for the correlation coefficients.
Table 2 | Correlates of 24,25(OH)2D as determined using
multiple linear regression
Model 1 Model 2 Model 3
Variables Coefficient P-value Coefficient P-value Coefficient P-value
Age (per 10 years) 0.08 0.159 0.05 0.442 0.02 0.696
Sex 0.05 0.835 0.19 0.382 0.26 0.182
Race
Non-Hispanic white Reference Reference Reference
Non-Hispanic black 0.82 o0.001 0.95 o0.001 0.57 0.003
Other 0.20 0.307 0.28 0.162 0.26 0.18
eGFR (ml/min per 1.73m2)
460 Reference Reference Reference
45–59 0.30 0.276 0.30 0.251 0.36 0.183
30–44 1.11 o0.001 1.11 o0.001 0.99 o0.001
15–29 1.17 o0.001 1.15 o0.001 1.21 o0.001
o15 1.65 o0.001 1.56 o0.001 1.61 0.001
25(OH)D 0.10 o0.001 0.10 o0.001 0.10 o0.001
Calcitriol use 0.06 0.842 0.08 0.804
Cholecalciferol use 0.21 0.323 0.01 0.955
Serum bicarbonate
(mg/dl)
0.05 0.011 0.05 0.019
Diabetes 0.46 0.007 0.63 o0.001
Urine ACR (mg/g, per
twofold higher ACR)
0.06 0.042 0.05 0.057
Body mass index
(kg/m2)
0.01 0.286 0.004 0.708
1,25(OH)2D (pg/ml) 0.02 0.001
PTH (pg/ml, per
twofold higher PTH)
0.33 o0.001
FGF-23 (pg/ml, per
twofold higher FGF-23)
0.11 0.329
Abbreviations: ACR, albumin to creatinine ratio; eGFR, estimated glomerular
filtration rate; FGF-23, fibroblast growth factor-23; 25(OH)D, 25-hydroxyvitamin;
1,25(OH)2D, 1,25-dihydroxyvitamin D; 24,25(OH)2D, 24,25-dihydroxyvitamin D; PTH,
parathyroid hormone.
All covariates adjusted for the other covariates included in each model.
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measurements a mean of 1.9 years (s.d.±0.9) after the baseline
examination, 24,25(OH)2D intraclass correlation coefficient, a
measure of intra-individual variation, was 0.75 (95% CI 0.56–0.94).
Serum concentrations of 1,25(OH)2D2 and 1,25(OH)2D3
were measured by immunoaffinity extraction and HPLC-mass
spectrometry (Xevo TQ, Waters), which has been previously
described.29 The method has lower limits of quantification (20%
coefficient of variation) of 1.25 pg/ml for 1,25(OH)2D3 and 0.64 pg/
ml for 1,25(OH)2D2. Published interassay and intraassay impreci-
sion for this method, for both 1,25(OH)2D3 and 1,25(OH)2D2, are
o14%. We report total 1,25(OH)2D as the sum of 1,25(OH)2D2
and 1,25(OH)2D3.
Measurement of covariates
Race, ethnicity, and smoking status were ascertained by question-
naire. Diabetes was defined as fasting blood glucose 4126mg/dl,
non-fasting blood glucose4200mg/dl, hemoglobin A1cX6.5%, or
use of glucose-lowering medications.38 Blood pressure was measured
three times 5min apart on an automated sphygmomanometer, and
the last two measurements were averaged for analysis. Hypertension
was defined as systolic blood pressure X140mmHg, diastolic blood
pressure X90mmHg, or use of antihypertensive medications.39
CAD was defined as history of myocardial infarction, cardiac arrest,
coronary artery bypass graft, or percutaneous coronary intervention.
Medications were ascertained from the computerized pharmacy
database for participants from the VAPSHC or by direct transcrip-
tion of medication bottle labels for the participants at HMC.
Baseline laboratory measurements were obtained from serum
and urine that were stored at 80 1C. General chemistries were
measured on a Beckman-Coulter DxC autoanalyzer (Beckman-
Coulter, Brea, CA). Urine albumin was measured by a timed end
point method, and urine creatinine was measured with the modified
rate Jaffe method. Serum creatinine was measured by the modified
rate Jaffe method with an assay traceable to isotope dilution mass
spectrometry. The CKD-Epi formula was used to calculate eGFR.40
Serum PTH was measured with the Beckman-Coulter DxI
automated immunoassay. Hyperparathyroidism was defined as
intact PTH concentration above 88 pg/ml (upper limit of normal
for assay). Intact FGF-23 was measured via ELISA (Kainos
Laboratories, Tokyo, Japan).
Ascertainment of death
Deaths were identified during twice yearly surveillance calls and
through linkage with the Social Security Death Index. Living
participants were censored at the date of their last SKS contact. As
of 31 December 2010, 57 of the 531 SKS participants had either
withdrawn or were lost to follow-up.
Statistical analysis
Cross-sectional analyses included the 278 participants in the
randomly selected cohort. We tabulated participant characteristics
by 24,25(OH)2D concentration, categorized as high or low using the
cohort population median value (2.4 ng/ml). We examined the
interrelationships of 24,25(OH)2D with 25(OH)D, 1,25(OH)2D,
PTH, and eGFR using Pearson’s correlation coefficients, scatter plots,
and fractional polynomials (second degree). We used multivariable
linear regression to assess independent determinants of 24,25(OH)2D.
Primary analyses evaluated 24,25(OH)2D concentration without
transformation; results examining log-transformed 24,25(OH)2D
concentration were similar except where noted. Age, sex, race,
cholecalciferol use, calcitriol use, 25(OH)D concentration, eGFR
(categories), log-transformed urine ACR (log(ACR)), and body mass
index were forced into the model. Diabetes, CAD, smoking, serum
albumin, serum phosphate, and serum bicarbonate were tested for
inclusion in the final model and retained if they were significantly
associated with 24,25(OH)2D (Po0.05). Parallel linear regression
models were used to assess determinants of PTH. We tested
associations of 24,25(OH)2D with death using Cox proportional
hazards regression. We used the Barlow method to account
for the case–cohort study design41 and stratified by clinic site.
We computed Kaplan–Meier survival estimates by weighting
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Figure 5 |Correlations of parathyroid hormone with
circulating vitamin D metabolites. (a) 24,25-dihydroxyvitamin D
(24,25(OH)2D), (b) 25-hydroxyvitamin D (25(OH)D), and (c) 1,25-
dihydroxyvitamin D (1,25(OH)2D). Line fit with linear regression.
P-values are for the correlation coefficients.
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individual observations according to the inverse of their
estimated sampling probability.42
Analyses were performed using Stata version 11.1 (Stata, College
Station, TX) and R 2.12.1 (http://www.r-project.org). All P-values
are two-sided, and values o0.05 were considered significant.
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